Found: 12
Select item for more details and to access through your institution.
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00351-4
- By:
- Publication type:
- Article
Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research.
- Published in:
- Cancers, 2023, v. 15, n. 17, p. 4364, doi. 10.3390/cancers15174364
- By:
- Publication type:
- Article
Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
- Published in:
- Cancers, 2022, v. 14, n. 5, p. 1101, doi. 10.3390/cancers14051101
- By:
- Publication type:
- Article
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 2, p. 351, doi. 10.1007/s10549-015-3616-8
- By:
- Publication type:
- Article
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.645026
- By:
- Publication type:
- Article
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 1, p. 75, doi. 10.1007/s00280-003-0690-0
- By:
- Publication type:
- Article
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.
- Published in:
- European Journal of Cancer Care, 2019, v. 28, n. 6, p. N.PAG, doi. 10.1111/ecc.13164
- By:
- Publication type:
- Article
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-019-14111-3
- By:
- Publication type:
- Article
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
- Published in:
- Breast Cancer Research, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13058-023-01649-w
- By:
- Publication type:
- Article